The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1308
March 23, 2009
View Complete Issue         Table of Contents 2019 
Focalin XR for ADHD
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Focalin XR for ADHD
March 23, 2009 (Issue: 1308)
Short-acting methylphenidate (MPH) is effective for treatment of attention-deficit/hyperactivity disorder (ADHD), but its 3-5 hour duration of action usually requires mid-day dosing in school, which children may find disruptive or stigmatizing.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Focalin XR for ADHD
Article code: 1308b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.